Efexor XL 225 mg hard prolonged-release capsules

Country: United Kingdom

Language: English

Source: myHealthbox

Buy It Now

Active ingredient:

venlafaxine hydrochloride,

Available from:

Pfizer Limited

ATC code:

NO6AX16

INN (International Name):

venlafaxine hydrochloride,

Dosage:

225 mg

Pharmaceutical form:

Hard prolonged-release capsule.

Administration route:

oral use

Units in package:

7, 10, 14, 15, 20, 28, 30, 50, 56, 60, 98, 100

Prescription type:

POM - Prescription Only Medicine

Manufactured by:

Pfizer Ireland Pharmaceuticals

Therapeutic group:

Other antidepressants

Therapeutic indications:

Treatment of major depressive episodes. For prevention of recurrence of major depressive episodes. Treatment of generalised anxiety disorder. Treatment of social anxiety disorder. Treatment of panic disorder, with or without agoraphobia.

Authorization status:

Authorised

Authorization date:

2015-11-26

Patient Information leaflet

                                 
Page 1 of 11
  
 
 
PACKAGE LEAFLET: INFORMATION FOR THE USER 
 
EFEXOR XL 225 MG HARD PROLONGED-RELEASE CAPSULES 
 
 
Venlafaxine 
 
IMPORTANT THINGS YOU SHOULD KNOW ABOUT EFEXOR XL  
 
PLEASE READ ALL OF THIS LEAFLET BEFORE YOU START TO TAKE YOUR
MEDICINE BECAUSE IT CONTAINS IMPORTANT 
INFORMATION FOR YOU. 
 
 
EFEXOR XL IS USED TO TREAT DEPRESSION, SEVERE AND
PERSISTENT ANXIETY KNOWN AS GENERALISED 
ANXIETY DISORDER (GAD), SOCIAL ANXIETY DISORDER (ALSO
KNOWN AS SOCIAL PHOBIA) AND PANIC 
DISORDER (PANIC ATTACKS) 
 
 
EFEXOR XL IS NOT FOR USE IN CHILDREN AND ADOLESCENTS – see
in section 2 ‘ Children and 
adolescents’  
 
IF YOU HAVE ANY CONCERNS ABOUT HOW YOU FEEL, OR ABOUT
THIS MEDICATION, IT IS IMPORTANT THAT YOU TALK 
TO YOUR DOCTOR - EVEN IF YOU FEEL ANXIOUS OR WORRIED ABOUT DOING
SO.   
You may find it helpful to tell a friend or relative that you
are depressed or suffering from an anxiety 
disorder, and that you have been prescribed this
medication; it might be useful to show them this leaflet. 
 
 
EFEXOR XL MAY NOT START TO WORK IMMEDIATELY.  Some
people taking antidepressants may feel 
worse before feeling better.  Your doctor may ask to see you
again a couple of weeks after you 
start treatment and then regularly until you start to
feel well again.  Tell your doctor if you do not 
start to feel better.  
 
 
SOME PEOPLE WHO ARE DEPRESSED MAY THINK OF HARMING OR KILLING
THEMSELF.  IF THIS HAPPENS 
YOU SHOULD SEE YOUR DOCTOR OR GO TO A HOSPITAL STRAIGHT
AWAY – see in section 2 ‘Thoughts of 
suicide and worsening of your depression or anxiety disorder’ 
 
 
IF YOU TAKE TOO MANY CAPSULES IT IS IMPORTANT TO
SEEK IMMEDIATE MEDICAL ATTENTION, EVEN IF 
YOU FEEL WELL, BECAUSE OF THE RISK OF SERIOUS SIDE EFFECTS 
 
 
DO NOT STOP TAKING EFEXOR XL OR CHANGE YOUR
DOSE WITHOUT THE ADVICE OF YOUR
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                (IH[RU;/PJ&DSVXOHV
6XPPDU\RI3URGXFW&KDUDFWHULVWLFV8SGDWHG1RY_3IL]HU/LPLWHG
1DPHRIWKHPHGLFLQDOSURGXFW
(IH[RU;/PJKDUGSURORQJHGUHOHDVHFDSVXOHV
4XDOLWDWLYHDQGTXDQWLWDWLYHFRPSRVLWLRQ
(DFKSURORQJHGUHOHDVHFDSVXOHFRQWDLQVPJRIYHQODID[LQHK\GURFKORULGHHTXLYDOHQWWRPJRIYHQODID[LQH
IUHHEDVH
)RUWKHIXOOOLVWRIH[FLSLHQWVVHHVHFWLRQ
3KDUPDFHXWLFDOIRUP
+DUGSURORQJHGUHOHDVHFDSVXOH
/LJKWJUH\RSDTXHFDSDQGGDUNRUDQJHRSDTXHERG\FDSVXOHVSULQWHGLQZKLWHZLWK
: DQG  KDUGJHODWLQFDSVXOH
VL]HHOPP[PP
&OLQLFDOSDUWLFXODUV
7KHUDSHXWLFLQGLFDWLRQV
7UHDWPHQWRIPDMRUGHSUHVVLYHHSLVRGHV
)RUSUHYHQWLRQRIUHFXUUHQFHRIPDMRUGHSUHVVLYHHSLVRGHV
7UHDWPHQWRIJHQHUDOLVHGDQ[LHW\GLVRUGHU
7UHDWPHQWRIVRFLDODQ[LHW\GLVRUGHU
7UHDWPHQWRISDQLFGLVRUGHUZLWKRUZLWKRXWDJRUDSKRELD
3RVRORJ\DQGPHWKRGRIDGPLQLVWUDWLRQ
3RVRORJ\
0DMRUGHSUHVVLYHHSLVRGHV
7KHUHFRPPHQGHGVWDUWLQJGRVHIRUSURORQJHGUHOHDVHYHQODID[LQHLVPJJLYHQRQFHGDLO\3DWLHQWVQRWUHVSRQGLQJWR
WKHLQLWLDOPJGD\GRVHPD\EHQHILWIURPGRVHLQFUHDVHVXSWRDPD[LPXPGRVHRIPJGD\'RVDJHLQFUHDVHV
FDQEHPDGHDWLQWHUYDOVRIZHHNVRUPRUH,IFOLQLFDOO\ZDUUDQWHGGXHWRV\PSWRPVHYHULW\GRVHLQFUHDVHVFDQEH
PDGHDWPRUHIUHTXHQWLQWHUYDOVEXWQRWOHVVWKDQGD\V
%HFDXVHRIWKHULVNRIGRVHUHODWHGDGYHUVHHIIHFWVGRVHLQFUHPHQWVVKRXOGEHPDGHRQO\DIWHUDFOLQLFDOHYDOXDWLRQ
VHHVHFWLRQ7KHORZHVWHIIHFWLYHGRVHVKRXOGEHPDLQWDLQHG
3DWLHQWVVKRXOGEHWUHDWHGIRUDVXIILFLHQWSHULRGRIWLPHXVXDOO\VHYHUDOPRQWKVRUORQJHU7UHDWPHQWVKRXOGEH
UHDVVHVVHGUHJXODUO\RQDFDVHE\FDVHEDVLV/RQJHUWHUPWUHDWPHQWPD\DOVREHDSSURSULDWHIRUSUHYHQWLRQRI
UHFXUUHQFHRIPDMRUGHSUHVVLYHHSLVRGHV0'(,QPRVWRIWKHFDVHVWKHUHFRPPHQGHGGRVHLQSUHYHQWLRQRI
UHFXUUHQFHRI0'(LVWKHVDPHDVWKHRQHXVHGGXULQJWKHFXUUHQWHSLVRGH
$QWLGHSUHVVLYHPHGLFLQDOSURGXFWVVKRXOGFRQWLQXHIRUDWOHDVWVL[PRQWKVIROORZLQJ
                                
                                Read the complete document